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cost-effective. CONCLUSIONS: While the current practice of recommending DMT 
for any patient with progressive MS results in substantial health gains, these gains
come at a very high drug cost, rendering the incremental cost-effectiveness ratios of 
each of the DMTs far above currently accepted standards.
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AND NECK, AND NON–SMALL CELL LUNG CANCER
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OBJECTIVES: Chemotherapy-associated peripheral neuropathy (CAPN) is a painful 
side-effect of chemotherapy. Comprehensive measures of health outcomes, medical
costs, and workloss burden of CAPN in patients with breast, ovarian, head/neck, or
non-small cell lung cancer (NSCLC) have not been quantiﬁ ed. This study assesses the
outcomes and direct and indirect cost burden of CAPN in these four tumor types from 
a third-party payer perspective. METHODS: Data were from an administrative claims
database of privately insured companies covering 1999–2006. Patients with qualifying 
tumors, and claims for chemotherapy and services indicative of peripheral neuropathy 
(PN) within 9-months of chemotherapy were selected. Cases were matched 1:1 to
controls with no PN-related claims based on cancer type, diabetes history, demograph-
ics, and propensity for reporting PN claims during the study period (estimated on
baseline resource use and comorbidities). Direct costs and resource use were calculated 
for a 12-month study period using diagnosis and procedure codes, pharmacy claims,
and provider specialty codes. Indirect costs were obtained for a subset of patients that
had disability and medically related absenteeism data. Comparisons of cost and
resource use between cases and controls used paired t-tests. RESULTS: Among patients
treated for breast, ovarian, head/neck, and NSCLC, 454 were identiﬁ ed who met 
inclusion criteria and had evidence of CAPN. Average direct costs were $17,344 higher
for CAPN cases than non-CAPN controls (p  0.0001). Outpatient costs were the 
highest component for both cases and controls with cases having excess outpatient
costs of $8092 (p  0.001). On average, each CAPN case had 12 more outpatient 
visits than controls (51.3 vs. 39.8 visits; p  0.0001), and spent more days in the hos-
pital (5.6 vs. 3.2 days; p  0.001). Indirect resource use and costs were higher for
cases but not statistically different from controls. CONCLUSIONS: CAPN is associ-
ated with increased direct medical cost and resource use of patients with breast,
ovarian, head/neck, or NSCLC.
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Rattinger GB1, DeLisle S2, Onukwugha E1, Mullins CD1
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland
School of Medicine and VA Maryland Health Care System, Baltimore, MD, USA
OBJECTIVES: Dementia patients often receive cholinesterase inhibitors and/or 
memantine (CIM) for cognitive symptoms, and antidepressants (AD) for behavioral 
symptoms. Ideally, patient demographics or clinic locations have no effect on care
received. We explored whether patient demographics and/or outpatient referrals to
specialized dementia or mental health clinics inﬂ uenced the likelihood of receiving 
CIM/AD medications. METHODS: Veteran’s Affairs Maryland Health Care System 
(VAMHCS) electronic medical records were used to select a cohort, based on diagnosis 
codes or medications indicating Alzheimer’s or related dementias. Patients aged 60 
and above, with index dates after 1999 were selected. Additional criteria included:
minimum of one year follow up or death within a year of index date. The outcome
(referent) was categorized as: receipt of CIM, receipt of AD, receipt of both CIM/AD 
(receipt of neither medication type). Multivariable multinomial logistic models (MLM)
explored predictors of CIM and AD utilization categories, including age, time in
cohort, race, marital status, and referrals to dementia or mental health clinics.
RESULTS: A cohort of 1359 patients, average age of 78.1 (SD 6.0) years and 22% 
African-Americans, was followed up for an average of 3.1 (SD 1.9) years. Thirty-ﬁ ve
percent had mental health or dementia clinic visits while 18% visited both clinics.
Signiﬁ cant associations were found for receiving both CIM and AD medications versus 
receiving no medication for years in cohort (OR  1.237, p  0.0001), African-Ameri-
can race (OR  0.437, p  0.0001), age (OR  0.966, p  0.0288),) marital status 
(OR  1.492, p  0.0339) and mental health clinic visit (OR  3.386, p  0.0001). 
Dementia clinic visit was associated with CIM only but not receipt of both medications
(OR  1.405, p  0.0996). CONCLUSIONS: In veterans with possible dementia, 
demographic factors and care at dementia/mental health clinics impact the likelihood 
of receiving CIM/AD medications. These found associations need to be further inves-
tigated for their potential impact on patient outcome.
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OBJECTIVES: To estimate the cost-utility of interferon-beta-1b (IFNB-1b) for the
treatment of patients with a clinically isolated syndrome (CIS) suggestive of multiple
sclerosis (MS) using ﬁ ve year BENEFIT clinical trial data. METHODS: We developed 
a Markov model of the epidemiology and treatment of CIS and MS. A hypothetical 
cohort of 1000 patients with incident CIS, with initial health states deﬁ ned by Kurtz-
ke’s Expanded Disability Symptom Scale (EDSS), was speciﬁ ed. The cohort was
assumed to be treated with either IFNB-1b (250 mcg eod) following an initial demye-
linating event suggestive of MS or not treated until conﬁ rmation of Poser-deﬁ ned MS. 
Data from BENEFIT were used to model EDSS transitions and transition from CIS 
to MS. Relapses were estimated from BENEFIT and published natural history data.
Following transition to MS, all patients were assumed to be treated with IFNB-1b
until reaching EDSS 6.5. Direct and indirect medical costs of MS treatment and IFNB-
1b were estimated using published literature and pricing schedules. Patient utilities
were derived from EQ-5D data from BENEFIT, supplemented by published data 
deﬁ ned by EDSS score and relapse occurrence. Mortality was estimated using life 
tables and EDSS data. Costs (2007 AUD) and outcomes were discounted at 5% per 
annum. Sensitivity analyses were performed on all key model parameters. RESULTS:
Use of IFNB-1b was associated with fewer EDSS transitions, longer time to CDMS
diagnosis, and a reduced relapse burden. In the base case (Australian perspective; 25-
year time horizon), the incremental cost utility of IFNB-1b versus no treatment was 
AUD 20,000 (USD 14,000) per quality-adjusted life year (QALY) gained. Findings 
were sensitive to time horizon, IFNB-1b cost and treatment effect, and underlying 
rate of disease progression. CONCLUSIONS: This model shows that IFNB-1b treat-
ment of patients with CIS is cost-effective with a cost per QALY gained within the 
range of many well accepted health care interventions.
PODIUM SESSION IV: HEALTH CARE MANAGEMENT STUDIES
HM1
EFFICIENCY AND ECONOMIC BENEFITS ASSOCIATED WITH THE USE
OF A PAYER–BASED ELECTRONIC HEALTH RECORD IN AN EMERGENCY
DEPARTMENT AMONG A HEALTH INSURED POPULATION
Daniel GW1, Ewen E2, Willey VJ3, Shirazi M4, Malone DC5
1HealthCore, Wilmington, DE, USA, 2Christiana Care Health System, Newark, DE, USA, 
3University of the Sciences in Philadelphia, Philadelphia, PA, USA, 4University of Arizona
College of Medicine, Tucson, AZ, USA, 5University of Arizona College of Pharmacy, Tucson, 
AZ, USA
OBJECTIVES: Health information exchange technologies are being implemented
widespread with goals of improving efﬁ ciency and costs of care. The need for timely, 
accurate, and pertinent information is most critical in the emergency department (ED).
This study evaluated the use of a payer-based electronic health record (P-EHR), which 
includes a clinical summary of a patient’s medical and pharmacy claims, in an ED on
length of stay (LOS) and costs of care among a commercially insured population. 
METHODS: A large urban hospital implemented a P-EHR in the ED. The P-EHR 
was evaluated using administrative claims and supplemental hospital data. Encounters
with P-EHR use were identiﬁ ed from claims between September 1, 2005 and February 
17, 2006. Accounting for seasonal variation, historical comparison encounters were
identiﬁ ed from November 1, 2004 to March, 31, 2005. Outcomes included ED LOS 
and cost for the ED encounter. Control variables included age, gender, pre-encounter
six month health care utilization and costs, comorbidity burden, plan type, day of 
week (weekend vs weekday), primary diagnosis, triage severity scores, and ED census. 
Analyses used multivariate generalized linear models and non-parametric bootstrap
for standard errors of predictions. RESULTS: A total of 2288 ED encounters were 
analyzed (779 P-EHR/1509 comparison). ED-only P-EHR encounters were discharged 
19 minutes quicker (95%CI:5–33 minutes) as compared to encounters not associated 
with the P-EHR. Among encounters resulting in hospitalization, the P-EHR was 
associated with a 77 minute reduction in LOS (95%CI:28–126 minutes) as compared
to non-P-EHR encounters. The use of the P-EHR was also associated with $1560 
(95% CI:$43–$2910) savings in total plan expenditures for encounters resulting in 
hospitalization. No signiﬁ cant difference in costs was observed among ED-only 
encounters. CONCLUSIONS: This study highlights that a P-EHR can have a meaning-
ful impact on ED throughput and costs. These beneﬁ ts may translate into improvement
in the care provided to patients and their satisfaction.
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OBJECTIVES: To determine the cost savings resulting from speciﬁ c pharmacist inter-
ventions provided to patients with diabetes and their physicians, using a decision-
analysis modeling approach. METHODS: Prospective, cohort study using Lucas
County employees with diabetes enrolled in an employer-sponsored Medication
Therapy Management program in Northwest Ohio. An expert (comprising of clinical 
pharmacists and researchers) opinion guided clinical model pathway was developed to 
identify and map speciﬁ c pharmacist interventions to corresponding responses and
outcomes. Interventions included: 1) alerting physician of patient’s abnormal A1c 
and/or blood sugar proﬁ le; 2) pattern management; 3) instructing on the proper use of 
injectable; 4) glucometer training; 5) advising patients on best way to correct hypogly-
cemic/hyperglycemic episodes. Data was extracted from patient charts and entered into
Microsoft Excel. A 1-year decision-analytic model was constructed using The TreeAge
Pro Suite 2008 to identify the cost-savings per intervention. Probabilities for the inter-
ventions, responses, and outcomes were obtained from real-world data. For example,
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the positive response ratio was calculated by dividing the number of patients who fol-
lowed the pharmacist advice to total number of patients to whom the advice was pro-
vided. The cost saving per patient per year was determined from available literature. 
RESULTS: A total of 180 interventions were made by the pharmacists. Pattern manage-
ment (100 cases, 55.5%) and alerting physician of an abnormal A1c (61, 33.8%) were
the most frequent. The most accepted interventions were glucometer training (2 cases, 
100%), advising to correct hypoglycemic/hyperglycemic episodes (12, 66.7%), and 
instructing on the proper use of their injectables (5, 60.0%). Cost savings of $1914/
patient/year were estimated as a result of the 4th and 5th intervention. Also, interven-
tions 1, 2 and 3 resulted in cost-saving of $1161, $ 1203, and $1531 per patient per 
year respectively. CONCLUSIONS: Our model showed that pharmacist interventions 
can result in signiﬁ cant cost savings among diabetic patients.
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OBJECTIVES: To evaluate the impact of a specialty care management program (Pre-
cisionRx Pharmacy Management) on medication adherence, risk of hospitalization, 
and costs of care among MS patients. METHODS: This study was a retrospective 
analysis of administrative claims from 13 geographically dispersed US commercial
health plans. Patients aged 18–64 years with q2 claims of MS diagnosis and q1 MS
medications (Interferon beta-1a, Interferon beta-1b, and Glatiramer acetate) from
January 1, 2004 and April 30, 2008 were identiﬁ ed. For patients enrolled in Preci-
sionRx program (managed), index date was deﬁ ned as the program participation date; 
for other patients (non-managed), index date was randomly assigned through Monte
Carlo simulation with regard to the managed patients. At least 12 months of continu-
ous eligibility pre- and post- index was required. Outcome metrics included medication 
adherence (measured by medication possession ratio (MPR)), risk of MS-related
hospitalization, and MS-related costs. Multivariate analyses were performed to adjust
for baseline demographics, baseline health care costs, and clinical characteristics. 
RESULTS: Among 3862 patients identiﬁ ed, 79% were managed and 21% were non-
managed patients. The multivariate analysis showed that compared with the non-
managed group, the managed group had 0.21 higher MPR (95% CI: 0.19–0.23, p 
0.001), were less likely to be hospitalized for MS (adjusted odds ratio: 0.53 (0.40–
0.70), p  0.001), and had 25% higher MS-related costs (95% CI: 20%-31%, p 
0.001), controlling for other covariates. The relatively larger increase in MS-related 
costs from pre-index to post-index among the managed group (median: $3791 vs. 
$2277) was primarily driven by larger increase in their pharmacy costs (median: $3968 
vs. $1885). CONCLUSIONS: Overall, this specialty care management program was 
associated with better medication adherence and lower risk of MS-related hospitaliza-
tion. The associated higher MS-related costs among the managed group could be
explained by their relatively larger increase in pharmacy costs, as expected due to
better medication adherence and high costs of MS medication.
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OBJECTIVES: To determine if differences existed between the intervention group 
[after participating in a pharmacist-provided telephone medication therapy manage-
ment (PPMTM) program] and the control group in: 1) Medication/health-related 
problems (MHRPs); 2) Medication adherence; and 3) Total Part D drug costs. 
METHODS: This quasi-experimental study of Part D beneﬁ ciaries from a Texas health 
plan used the Andersen Model as its theoretical framework. Predisposing factors were 
age, gender, and race; need factors were number of medications, number of chronic 
diseases and medication regimen complexity. The intervention and control groups
were matched on number of medications and number of chronic diseases. The health 
behavior was PPMTM participation. Outcomes were changes in: 1) Number of 
MHRPs; 2) Medication adherence using medication possession ratio (MPR); and 3)
Total drug costs. Multivariate regression was used for group comparisons of outcomes.
RESULTS: The intervention (n  60) and control (n  60) groups were not statistically 
different in predisposing or need factors except for gender (intervention  51.7% male; 
control  28.3% male; p  0.009). At baseline, 4.8 (o2.7) MHRPs were identiﬁ ed in 
the intervention group and 9.2 (o2.9) in the control group. At the 6-month follow-up, 
2.5 (o2.0) and 7.9 (o3.0) MHRPs remained, respectively. Multivariate regression
revealed that the intervention group had signiﬁ cantly more MHRPs resolved (p 
0.0003) when compared to the control group, while controlling for predisposing and 
need factors. There were no other signiﬁ cant predictors of MHRP resolution, Analyses 
showed no signiﬁ cant predictors of change in MPR or total drug costs from baseline
to 6-month follow-up. CONCLUSIONS: A telephone MTM program was effective in
resolving MHRPs among Medicare beneﬁ ciaries; however, no signiﬁ cant differences 
existed between the intervention and control groups in medication adherence and total 
drug costs.
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OBJECTIVES: The initiation of Medicare Part D in 2006 offers an ideal opportunity
to study real-world decision-making and the role of adverse selection and other factors 
in insurance enrollment. Our objective was to identify predictors of Part D enroll-
ment among individuals with a range of health conditions and insurance designs. 
METHODS: The sample included all individuals in both the 2005 and 2006 Medical 
Expenditure Panel Survey (MEPS) datasets who were enrolled in Medicare, but not 
Medicaid, as of December 2005. A multivariate logistic regression was used to assess 
the effects of sociodemographics, health status, 2005 supplemental insurance cover-
age, and 2005 person-level out-of-pocket (OOP) drug expenditures on the likelihood 
of enrolling in Part D in 2006. MEPS sample weights were used to calculate standard 
errors. RESULTS: Out of 1,436 persons who met inclusion criteria, 657 (45.4%) 
enrolled in Part D during 2006. Compared to the no-Part D group, the Part D group 
was slightly older, had more non-whites, rural residents, and unmarried individuals,
and was slightly less educated and poorer. The Part D group had more beneﬁ ciaries
with Medigap coverage only (17.2% vs. 5.7%), fewer with employer-based coverage 
only (18.3% vs. 37.1%), and more with no private supplemental insurance (46.1% 
vs. 32.1%). In multivariate analyses, signiﬁ cant positive predictors of Part D enroll-
ment were having Medigap supplemental insurance only (OR: 1.99; 95% CI: 1.25–
3.19) and OOP drug expenditures q$2500 in 2005 (OR: 1.58; 95% CI: 1.03–2.41).
Most beneﬁ ciaries with employer-based coverage in 2005 maintained that coverage in
2006 (91.8%). CONCLUSIONS: Based on ﬁ rst-year data, fears of only the sickest
beneﬁ ciaries enrolling in Part D and employers withdrawing drug beneﬁ ts to retirees
seem to have been unwarranted. Existing coverage and high prior drug spending drove
the decision to enroll in Part D in what appears to have been a rational way.
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OBJECTIVES: The objectives were to describe angiotensin-converting enzyme inhibi-
tors (ACEI) and angiotensin II receptor blockers (ARB) use among Medicare Part D 
enrollees with diabetes and to identify patient characteristics that predict ACEI/ARB
utilization. METHODS: This is a longitudinal retrospective cohort study. The study 
sample included Medicare Part D enrollees from 6 states (Alabama, California, 
Florida, Mississippi, New York, and Ohio) aged 18 years or older with the diagnosis
of diabetes. Medicare Part D claims data for the ﬁ rst 6 months of 2006 were evaluated
for any utilization of ACEI/ARB. The outcome of interest was the percentage of at
least one claim for an ACEI or an ARB during the ﬁ rst half of 2006. RESULTS: A
total of 1,888,682 patients met our inclusion criteria. Mean age (oSD) was 71.6 
(o11.6) years, 59.5% were female, and 66.4% were white. Approximately 58.9%,
5.8%, 0.5% had coexisting hypertension, nephropathy, and hypertension  nephropa-
thy. Overall, 56.9% were receiving ACEI/ARB therapy. Logistic regression indicated 
that patients with coexisting hypertension  nephropathy and hypertension were 72%
and 36% more likely to use ACEI/ARB compared to patients without hypertension
and/or nephropathy. However, patients with nephropathy were 24% less likely to
receive ACEI/ARB therapy. Females, older patients, and patients of nonwhite races 
were also more likely to use ACEI/ARB. Patients with myocardial infarction, sleep 
apnea, coronary artery disease, retinopathy or heart failure were more likely to have 
used ACEI/ARB, while the opposite was true for those with hypercholesterolemia, 
peripheral vascular, cerebrovascular, or chronic obstructive pulmonary diseases. All 
results were statistically signiﬁ cant at P  .0001 level. CONCLUSIONS: Less than
60% of Medicare Part D enrollees with diabetes received ACEI/ARB therapy. Several
patient characteristics can predict ACEI/ARB use. Opportunities exist for quality-
improvement interventions that could increase the outcomes for high-risk patients.
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OBJECTIVES: Despite the huge cost of the program, the Centers for Medicare and 
Medicaid Services (CMS) maintains that cost-effectiveness is not considered in national 
coverage determinations (NCDs) for medical technologies. Our objective was to assess 
the cost-effectiveness of technologies and interventions that are the subject of Medicare 
NCDs in order to investigate whether an implicit cost-effectiveness threshold exists. 
In addition, we explored whether CMS have cited cost-effectiveness evidence in NCDs. 
METHODS: We reviewed NCD decision memos from 1999 through 2007 (n  103). 
A literature review was conducted for each coverage decision to ﬁ nd relevant economic
evaluations. The economic evaluation that best represented each coverage decision 
was included in a review of the cost-effectiveness of medical technologies considered 
in NCDs. RESULTS: Sixty-four coverage decisions were identiﬁ ed from 103 decision 
memos. Fifty were associated with a positive coverage decision and 14 with a 
